Benzbromarone Therapy in Treatment-Resistant
Gout
Title: Benzbromarone therapy in management of
refractory gout.
Authors: Kumar S, et al.
Publication: N Z Med J. 2005 Jun 24;118(1217):U1528.
In this study, the authors wanted to assess the efficacy and
safety of benzbromarone medication in patients with kidney conditions
and severe gout with uric acid crytal deposits.
They enrolled 6 patients with gout that have resisted conventional
treatment in this study, and gave them benzbromarone. After 1
year of treatment, the average uric acid level was reduced by
approximately 25% from 0.61 mmol/L to 0.46 mmol/L. The frequency
of acute gout attack was also reduced from 16 (an average of the
span of 8 to 20 times affecting these patients) to 7.3 (the average
of a span of 1 o 16). Non patients reported adverse side effects
with benzbromarone and no acute gout flares resulted when the
medicines were first administered.
The authors concluded that benzbromarone is effective in reducing
uric acid levels and the number of gout attacks in patients that
failed to respond to conventional treatments.
Editor’s note: benzbromarone is a uricosuric agent,
which can lower uric acid levels in people with hyperuricemia (high
levels of uric acid in the blood) and gout.
